New Delhi: Mu kwanukula ekiteeso ekyakoleddwa Fresenius Medical Care, akakiiko k’abakugu mu by’obujjanjabi aka Specialty Expert Committee (SEC) ak’ekitongole ekivunaanyizibwa ku mutindo gw’eddagala ekya Central Drugs Standard Control Organization (CDSCO) kawadde kkampuni eno amagezi okuleeta ensonga lwaki egenda kukkirizibwa wamu n’ebikwata ku kugezesebwa okw’omutendera ogw’okusatu okwa calcium chloride dihydrate n’ebikwata ku kulondoola oluvannyuma lw’okutunda okuva mu mawanga agakkirizibwa okwongera okulowoozebwako.
Kkampuni eno emabegako yawaaba okusaba okukola n’okutunda calcium chloride dihydrate solution ku kigero kya 100 mmol/L, ekikozesebwa mu “obujjanjabi obukyusa calcium mu bujjanjabi obutasalako obw’okukyusa ekibumba (CRRT), continuous low-efficiency (daily) dialysis (CLED) n’okuwanyisiganya plasma mu bujjanjabi (TPE) n’eddagala lya citrate anticoagulation abaana” era n’alaga ensonga lwaki baggyiddwa mu kugezesebwa kw’obujjanjabi okw’omutendera III n’ogw’okuna.
Akakiiko kano kategeezezza nti ekintu kino kikkiriziddwa mu mawanga ga Bulaaya nga Portugal, Bungereza, Brazil, Switzerland, Bufalansa ne Denmark.
Ekirungo kya calcium chloride dihydrate ye CaCl2 2H2O, nga eno ye calcium chloride erimu molekyu bbiri ez’amazzi buli yuniti ya calcium chloride. Kiba kirungo kya kirisitaalo ekyeru, kinywera mangu mu mazzi era nga kikwata amazzi, kwe kugamba, kisobola okunyiga obunnyogovu okuva mu mpewo.
Calcium chloride dihydrate kirungo ekiyinza okukozesebwa ng’enkola y’ekizimbulukusa okusaanuusa chitin nga esaanuuse mu methanol. Kikola kinene mu kumenya ensengekera ya kirisitaalo ya chitin era kirina enkozesa nnyingi mu kisaawe kya kemiko.
Mu lukiiko lwa SEC Nephrology olwatuula nga May 20, 2025, akakiiko kano keekenneenya ekiteeso ky’okukkiriza okukola n’okutunda 100 mmol/L calcium chloride dihydrate infusion solution okukozesebwa mu “calcium replacement therapy in continuous renal replacement therapy (CRRT), continuous low-efficiency (daily) dialysis (SLEDD), n’okuwanyisiganya eddagala mu plasma (TPE) n’eddagala eriziyiza okuzimba omusaayi erya citrate.
Oluvannyuma lw’okukubaganya ebirowoozo mu bujjuvu, akakiiko kaawa amagezi nti omusingi gw’okukkiriza, wamu n’ebikwata ku kugezesebwa kw’obujjanjabi okw’omutendera ogw’okusatu n’ebikwata ku kulondoola oluvannyuma lw’okutunda okuva mu mawanga agakkiriza eddagala lino, biweebwe akakiiko okwongera okwetegereza.
Soma ne: Ekibiina kya CDSCO Kikkirizza Okuwandiika Ebipya ku Myozyme ya Sanofi, Kisabye Okuddamu okwetegereza amateeka
Dr. Divya Kolin yatikkirwa mu PharmD ng’alina obumanyirivu bungi mu bujjanjabi n’eddwaliro era ng’amanyi bulungi mu kuzuula n’okujjanjaba. Era abaddeko ng’omukugu mu by’eddagala mu by’obulwadde bwa kookolo mu kitongole ky’eby’obulwadde bwa kookolo mu Mysore Medical College and Research Institute. Mu kiseera kino akola omulimu gwe mu kunoonyereza ku bujjanjabi n’okuddukanya ebikwata ku bujjanjabi. Abadde akolagana ne Medical Dialogue okuva mu January 2022.
       Dr Kamal Kant Kohli, MBBS, MD, CP, is a thoracic specialist with over 30 years of experience and specializes in clinical writing. He joins Medical Dialogues as the Editor-in-Chief of Medical News. Apart from writing articles, as the Editor, he is responsible for proofreading and reviewing all medical content published in Medical Dialogues, including content from journals, research papers, medical conferences, guidelines, etc. Email: drkohli@medicaldialogues.in Contact: 011-43720751
Okunoonyereza kwa ABYSS kwazuula nti okuyimiriza eddagala lya beta-blockers oluvannyuma lw’okuzimba omusuwa gw’omutima kyavaamu puleesa, okukuba kw’omutima, n’ebizibu ebiva mu misuwa gy’omutima okweyongera: ...